Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The drug is in mid-stage clinical trials for IgAN, as well as primary membranous nephropathy (PMN) and antibody-mediated transplant rejection, and is in phase 1 for lupus nephritis. CD38 is found ...

Privately held HI-Bio's lead candidate is the biologic felzartamab that also targets CD38. It is under investigation for primary membranous nephropathy, antibody-mediated rejection, and IgA ...